A Phase 2 Pilot Trial of Low-Dose, Continuous Infusion, or Metronomic Paclitaxel and Oral Celecoxib in Patients With Metastatic Melanoma

Rupal S BHATT; Jaime MERCHAN; Robert PARKER; Hua-Kang WU; LIANG LIANG ZHANG; Virginia SEERY; John V HEYMACH; Michael B ATKINS; David MCDERMOTT; Vikas P SUKHATME

doi:10.1002/cncr.24902

Back

A Phase 2 Pilot Trial of Low-Dose, Continuous Infusion, or Metronomic Paclitaxel and Oral Celecoxib in Patients With Metastatic Melanoma

Journal article

Open access

Peer reviewed

A Phase 2 Pilot Trial of Low-Dose, Continuous Infusion, or Metronomic Paclitaxel and Oral Celecoxib in Patients With Metastatic Melanoma

Rupal S BHATT, Jaime MERCHAN, Robert PARKER, Hua-Kang WU, LIANG LIANG ZHANG, Virginia SEERY, John V HEYMACH, Michael B ATKINS, David MCDERMOTT and Vikas P SUKHATME

Cancer, Vol.116(7), pp.1751-1756

2010

DOI: https://doi.org/10.1002/cncr.24902

PMID: 20120033

Abstract

Tumors of the skin and soft tissue. Premalignant lesions

Biological and medical sciences

Medical sciences

Dermatology

Tumors

Files and links (1)

url

https://doi.org/10.1002/cncr.24902View

Published (Version of record) Open

Metrics

18 Record Views

57 Times Cited - Web of Science

InCites Highlights

These are selected metrics from InCites Benchmarking & Analytics tool, related to this output

Collaboration types: Domestic collaboration
Citation topics: 1 Clinical & Life Sciences; 1.102 Stem Cell Research; 1.102.170 Angiogenesis
Web Of Science research areas: Oncology
ESI research areas: Clinical Medicine

UN Sustainable Development Goals (SDGs)

This output has contributed to the advancement of the following goals:

Source: InCites

Details

Title: A Phase 2 Pilot Trial of Low-Dose, Continuous Infusion, or Metronomic Paclitaxel and Oral Celecoxib in Patients With Metastatic Melanoma
Creators: Rupal S BHATT - Division of Hematology and Oncology, Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
Jaime MERCHAN - Department of Hematology and Oncology, University of Miami, Miami, Florida, United States
Robert PARKER - Harvard School of Public Health, Boston, Massachusetts, United States
Hua-Kang WU - Department of Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, United States
LIANG LIANG ZHANG - Division of Hematology and Oncology, Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
Virginia SEERY - Division of Hematology and Oncology, Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
John V HEYMACH - Department of Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, United States
Michael B ATKINS - Division of Hematology and Oncology, Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
David MCDERMOTT - Division of Hematology and Oncology, Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
Vikas P SUKHATME - Interdisciplinary Medicine and Biotechnology, Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
Publication Details: Cancer, Vol.116(7), pp.1751-1756
Publisher: Wiley-Blackwell; Hoboken, NJ
Academic Unit: Miller School of Medicine; UMMG Dept of Medicine - Hematology/Oncology
Language: English
Resource Type: Journal article
PMID: 20120033
Record Identifier: 991031562979602976